Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Interest Expenses (2024 - 2025)

Caris Life Sciences has reported Interest Expenses over the past 2 years, most recently at $11.4 million for Q4 2025.

  • Quarterly results put Interest Expenses at $11.4 million for Q4 2025, down 14.37% from a year ago — trailing twelve months through Dec 2025 was $57.3 million (changed N/A YoY), and the annual figure for FY2025 was $56.9 million, up 13.65%.
  • Interest Expenses for Q4 2025 was $11.4 million at Caris Life Sciences, down from $13.5 million in the prior quarter.
  • Over the last five years, Interest Expenses for CAI hit a ceiling of $19.2 million in Q2 2025 and a floor of $11.4 million in Q4 2025.